Is Lipocine Inc. (LPCN) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 47.9% / 30% | 0.3% / 30% | 10.24% / 5% | ✗ NOT HALAL |
| DJIM | 0.0% / 33% | 47.9% / 33% | 0.3% / 33% | 10.24% / 5% | ✗ NOT HALAL |
| MSCI | 0.0% / 33% | 96.1% / 33% | 0.5% / 33% | 10.24% / 5% | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 47.9% / 33% | 0.3% / 33% | 10.24% / 5% | ✗ NOT HALAL |
| FTSE | 0.0% / 33% | 96.1% / 33% | 0.5% / 50% | 10.24% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 100.0% | |
| Operating Margin | -219.6% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -54.3% | |
| Return on Assets (ROA) | -32.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$10M |
| Free Cash Flow | -$10M |
| Debt-to-Equity | 3.1 |
| Current Ratio | 6.7 |
| Total Assets | $17M |
Price & Trading
| Last Close | $7.40 |
| 50-Day MA | $8.79 |
| 200-Day MA | $4.84 |
| Avg Volume | 149K |
| Beta | 1.0 |
|
52-Week Range
$2.52
| |
About Lipocine Inc. (LPCN)
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. It also develops LPCN 1154 (BRLIZIO), an oral neuro-steroid in a Phase 3 pivotal trial for postpartum depression; LPCN 1148, a prodrug of testosterone and testosterone laurate that has completed a Phase 2 trial for the management of decompensated cirrhosis; LPCN 1107, an oral hydroxy progesterone caproate product that has completed a Phase 2 trial for the prevention of recurrent preterm birth; LPCN 1144, an oral prodrug of bioidentical testosterone that has completed a Phase 2 trial for pre-cirrhotic non-alcoholic steatohepatitis; and LPCN 2401, an oral formulation comprising a proprietary anabolic androgen receptor agonist that is in a Phase 2 trial to manage incretin mimetic use in obesity management. In addition, the company is developing LPCN 2201, an oral brexanolone formulation that has completed a Phase 1 trial for major depressive disorders; LPCN 2203, an oral candidate that has completed a Phase 1 trial for management of essential tremor; and LPCN 2101, a neuroactive steroids (NAS) candidate that has completed a Phase 1 trial for drug-resistant epilepsy and women with epilepsy. The company's products focus on neurological and psychiatric central nervous system (CNS) disorders, liver disease, and hormone supplementation in the United States. It has a collaboration with Verity Pharmaceuticals, Inc. to develop and commercialize TLANDO; and TLANDO XR (LPCN 1111), a once-daily oral product candidate that has completed a Phase 2 trial for testosterone replacement therapy. Lipocine Inc. was founded in 1997 and is headquartered in Salt Lake City, Utah.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Lipocine Inc. (LPCN) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Lipocine Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Lipocine Inc.'s debt ratio?
Lipocine Inc.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are Lipocine Inc.'s key financial metrics?
Lipocine Inc. has a market capitalization of $52M, and revenue of $2M. Return on equity stands at -54.3%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.